280 related articles for article (PubMed ID: 28696792)
1. Direct-to-Consumer Genetic Testing and Orphan Drug Development.
Mason M; Levenson J; Quillin J
Genet Test Mol Biomarkers; 2017 Aug; 21(8):456-463. PubMed ID: 28696792
[TBL] [Abstract][Full Text] [Related]
2. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
[TBL] [Abstract][Full Text] [Related]
3. Proposed 'grant-and-access' program with price caps could stimulate development of drugs for very rare diseases.
Valverde AM; Reed SD; Schulman KA
Health Aff (Millwood); 2012 Nov; 31(11):2528-35. PubMed ID: 23129684
[TBL] [Abstract][Full Text] [Related]
4. Current landscape of direct-to-consumer genetic testing and its role in ophthalmology: a review.
Sanfilippo PG; Kearns LS; Wright P; Mackey DA; Hewitt AW
Clin Exp Ophthalmol; 2015 Aug; 43(6):578-90. PubMed ID: 25676199
[TBL] [Abstract][Full Text] [Related]
5. The impact of the Orphan Drug Act on Food and Drug Administration-approved therapies for rare skin diseases and skin-related cancers.
Karas L; Lu CY; Agrawal PB; Asgari MM
J Am Acad Dermatol; 2019 Sep; 81(3):867-877. PubMed ID: 31103566
[TBL] [Abstract][Full Text] [Related]
6. Direct-to-consumer misleading information on cancer risks calls for an urgent clarification of health genetic testing performed by commercial companies.
de Pauw A; Schwartz M; Colas C; Golmard L; Stoppa-Lyonnet D
Eur J Cancer; 2020 Jun; 132():100-103. PubMed ID: 32335476
[TBL] [Abstract][Full Text] [Related]
7. Direct-to-Consumer Genetic Testing: Finding a Clear Path Forward.
Seward B
Ther Innov Regul Sci; 2018 Jul; 52(4):482-488. PubMed ID: 29714553
[TBL] [Abstract][Full Text] [Related]
8. Internet-Based Direct-to-Consumer Genetic Testing: A Systematic Review.
Covolo L; Rubinelli S; Ceretti E; Gelatti U
J Med Internet Res; 2015 Dec; 17(12):e279. PubMed ID: 26677835
[TBL] [Abstract][Full Text] [Related]
9. The economics of orphan drug policy in the US. Can the legislation be improved?
Peabody JW; Ruby A; Cannon P
Pharmacoeconomics; 1995 Nov; 8(5):374-84. PubMed ID: 10160072
[TBL] [Abstract][Full Text] [Related]
10. Direct-to-Consumer Genetic Testing: Value and Risk.
Majumder MA; Guerrini CJ; McGuire AL
Annu Rev Med; 2021 Jan; 72():151-166. PubMed ID: 32735764
[TBL] [Abstract][Full Text] [Related]
11. Direct-to-consumer genetic testing: a systematic review of european guidelines, recommendations, and position statements.
Rafiq M; Ianuale C; Ricciardi W; Boccia S
Genet Test Mol Biomarkers; 2015 Oct; 19(10):535-47. PubMed ID: 26313927
[TBL] [Abstract][Full Text] [Related]
12. Direct-to-Consumer Testing 2.0: Emerging Models of Direct-to-Consumer Genetic Testing.
Allyse MA; Robinson DH; Ferber MJ; Sharp RR
Mayo Clin Proc; 2018 Jan; 93(1):113-120. PubMed ID: 29304915
[TBL] [Abstract][Full Text] [Related]
13. What the Orphan Drug Act has done lately for children with rare diseases: a 10-year analysis.
Thorat C; Xu K; Freeman SN; Bonnel RA; Joseph F; Phillips MI; Imoisili MA
Pediatrics; 2012 Mar; 129(3):516-21. PubMed ID: 22371464
[TBL] [Abstract][Full Text] [Related]
14. [European incentives for orphan medicinal products].
Enzmann H; Lütz J
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 May; 51(5):500-8. PubMed ID: 18696141
[TBL] [Abstract][Full Text] [Related]
15. Public Attitudes Toward Direct to Consumer Genetic Testing.
Ruhl GL; Hazel JW; Clayton EW; Malin BA
AMIA Annu Symp Proc; 2019; 2019():774-783. PubMed ID: 32308873
[TBL] [Abstract][Full Text] [Related]
16. A comprehensive study of the rare diseases and conditions targeted by orphan drug designations and approvals over the forty years of the Orphan Drug Act.
Fermaglich LJ; Miller KL
Orphanet J Rare Dis; 2023 Jun; 18(1):163. PubMed ID: 37353796
[TBL] [Abstract][Full Text] [Related]
17. Direct-to-consumer DNA testing and the GP.
Trent R
Aust Fam Physician; 2014 Jul; 43(7):436-9. PubMed ID: 25006602
[TBL] [Abstract][Full Text] [Related]
18. "Creating hope" and other incentives for drug development for children.
Connor E; Cure P
Sci Transl Med; 2011 Jan; 3(66):66cm1. PubMed ID: 21248312
[TBL] [Abstract][Full Text] [Related]
19. Do It Yourself Newborn Screening.
Borry P; Sénécal K; Knoppers BM
JAMA Pediatr; 2016 Jun; 170(6):523-4. PubMed ID: 27111240
[No Abstract] [Full Text] [Related]
20. The impact of the Orphan Drug Act on the development and advancement of neurological products for rare diseases: a descriptive review.
Burke KA; Freeman SN; Imoisili MA; Coté TR
Clin Pharmacol Ther; 2010 Oct; 88(4):449-53. PubMed ID: 20856241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
